New hope for bile duct cancer: targeted drug SHR-A1904 enters Mid-Stage trial

NCT ID NCT07450976

Recruiting now Disease control Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests an experimental drug called SHR-A1904 in people with advanced biliary tract cancer (bile duct cancer) that has not responded to previous treatments. The drug targets a protein called CLDN18.2 found on some cancer cells. The trial aims to see if the drug can shrink tumors and control the disease. About 151 participants will receive the drug until their cancer worsens or side effects become too severe.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SHR-A1904 (an experimental drug that targets a protein called CLDN18.2 on cancer cells)
What this could lead to: If successful, this could provide a new treatment option for people with advanced biliary tract cancer who have run out of standard therapies.
What could go wrong: This is an early Phase 2 trial with only 151 participants, so results may not apply to everyone. The drug may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

biliary tract cancer Biliary Tract Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BILIARY TRACT CANCER

Contacts and locations

Locations

Cancer Hospital, Chinese Academy of Medical Sciences
RECRUITING

Beijing, Beijing Municipality, 100021, China
Zhongshan Hospital, Fudan University
RECRUITING

Shanghai, Shanghai Municipality, 200032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.